Meta-analyses have demonstrated that EGFR-mutant NSCLC is less sensitive to ICI, which may be due, in part, to a more immunosuppressive TME in these tumors [138,145,149]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.